Clinical Trials Browser

Phase 2 × Lymphoma, T-Cell, Peripheral × sintilimab × Clear all

NCT04052659 2021-03-09

Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

Phase 2 Unknown

Lymphoma, T-Cell, Peripheral